mouse plgf2 quantikine elisa kit  (R&D Systems)

Journal: Archives of Toxicology

Article Title: Induction of hemangiosarcoma in mice after chronic treatment with S1P-modulator siponimod and its lack of relevance to rat and human

doi: 10.1007/s00204-018-2189-9

Figure Lengend Snippet: Mouse Placental Growth Factor 2 (PLGF2). Circle: control, triangle: low dose, square: high dose. Each dot represents terminal plasma value of 1 animal. The 2 circled points highlight the 2 mice bearing HSA. ** p < 0.01; **** p < 0.0001 (homoscedastic t test). Bar = Mean; error bar = 1 standard deviation

Article Snippet: In animals from groups 12 and 13 (animals treated for 13 weeks; repeated sublingual bleeding on day 3, day 25, and day 81; terminal bleeding on day 92), PLGF2 plasma concentrations were measured by an ELISA method using the Mouse PLGF2 Quantikine ELISA kit (R&D Systems, catalogue reference: MP200) with a VersaMax® ELISA microplate reader.

Techniques: Control, Clinical Proteomics, Standard Deviation

Journal: Archives of Toxicology

Article Title: Induction of hemangiosarcoma in mice after chronic treatment with S1P-modulator siponimod and its lack of relevance to rat and human

doi: 10.1007/s00204-018-2189-9

Figure Lengend Snippet: Rat Placental Growth Factor 2 (PLGF2). Circle: control, square: high dose. Bar = mean; error bar = 1 standard deviation. Horizontal-dotted line: LLoQ. Each dot represents terminal plasma value of 1 animal in part A, and same animals intermediate sampling values through time in part B. a PLGF2 terminal samples analyzed by Luminex multiplexed kit. b PLGF2 kinetics samples analyzed by ELISA

Article Snippet: In animals from groups 12 and 13 (animals treated for 13 weeks; repeated sublingual bleeding on day 3, day 25, and day 81; terminal bleeding on day 92), PLGF2 plasma concentrations were measured by an ELISA method using the Mouse PLGF2 Quantikine ELISA kit (R&D Systems, catalogue reference: MP200) with a VersaMax® ELISA microplate reader.

Techniques: Control, Standard Deviation, Clinical Proteomics, Sampling, Luminex, Enzyme-linked Immunosorbent Assay

Journal: Archives of Toxicology

Article Title: Induction of hemangiosarcoma in mice after chronic treatment with S1P-modulator siponimod and its lack of relevance to rat and human

doi: 10.1007/s00204-018-2189-9

Figure Lengend Snippet: Siponimod-treated mouse skeletal muscle VECs. Assessment of cell proliferation and PLGF2 release of mouse muscle VECs treated with Siponimod expressed as percentage of control untreated cells (solid symbols: average of three independent experiments with triplicate points within each experiment; open symbols: single experiment with triplicate points within each experiment)

Article Snippet: In animals from groups 12 and 13 (animals treated for 13 weeks; repeated sublingual bleeding on day 3, day 25, and day 81; terminal bleeding on day 92), PLGF2 plasma concentrations were measured by an ELISA method using the Mouse PLGF2 Quantikine ELISA kit (R&D Systems, catalogue reference: MP200) with a VersaMax® ELISA microplate reader.

Techniques: Control

Journal: Archives of Toxicology

Article Title: Induction of hemangiosarcoma in mice after chronic treatment with S1P-modulator siponimod and its lack of relevance to rat and human

doi: 10.1007/s00204-018-2189-9

Figure Lengend Snippet: Siponimod-treated rat pulmonary ( a ) and aortic VECs ( b ). Assessment of cell proliferation and PLGF2 release of rat pulmonary ( a ) and aortic ( b ) VECs treated with Siponimod expressed as percentage of control untreated cells (average of two independent experiments with triplicate points within each experiment)

Article Snippet: In animals from groups 12 and 13 (animals treated for 13 weeks; repeated sublingual bleeding on day 3, day 25, and day 81; terminal bleeding on day 92), PLGF2 plasma concentrations were measured by an ELISA method using the Mouse PLGF2 Quantikine ELISA kit (R&D Systems, catalogue reference: MP200) with a VersaMax® ELISA microplate reader.

Techniques: Control

Journal: Archives of Toxicology

Article Title: Induction of hemangiosarcoma in mice after chronic treatment with S1P-modulator siponimod and its lack of relevance to rat and human

doi: 10.1007/s00204-018-2189-9

Figure Lengend Snippet: Siponimod-treated human dermal and pulmonary VECs. Assessment of cell proliferation and PLGF2 release of human dermal ( a ) and pulmonary ( b ) VECs treated with Siponimod expressed as percentage of control untreated cells (average of three (pulmonary VECs) and two (dermal VECs) independent experiments with triplicate points within each experiment)

Article Snippet: In animals from groups 12 and 13 (animals treated for 13 weeks; repeated sublingual bleeding on day 3, day 25, and day 81; terminal bleeding on day 92), PLGF2 plasma concentrations were measured by an ELISA method using the Mouse PLGF2 Quantikine ELISA kit (R&D Systems, catalogue reference: MP200) with a VersaMax® ELISA microplate reader.

Techniques: Control

Journal: Archives of Toxicology

Article Title: Induction of hemangiosarcoma in mice after chronic treatment with S1P-modulator siponimod and its lack of relevance to rat and human

doi: 10.1007/s00204-018-2189-9

Figure Lengend Snippet: Mouse versus rat Adverse Outcome Pathway plausible mechanism for HSA formation in the mouse. Although PLGF2 induction was observed earlier than the mitosis gene signature, it is unknown if one flows from the other, or if both independently arise from VEC activation. The fact that in the rat, PLGF2 induction outlasts mitosis would tend to advocate for two separate events

Article Snippet: In animals from groups 12 and 13 (animals treated for 13 weeks; repeated sublingual bleeding on day 3, day 25, and day 81; terminal bleeding on day 92), PLGF2 plasma concentrations were measured by an ELISA method using the Mouse PLGF2 Quantikine ELISA kit (R&D Systems, catalogue reference: MP200) with a VersaMax® ELISA microplate reader.

Techniques: Activation Assay